Laboratory testing for lupus anticoagulants: A review of issues affecting results

Clinical Chemistry

Volumn 53, Issue 9, 2007, Pages 1629-1635

  Tripodi, Armando ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LUPUS ANTICOAGULANT;

CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; REVIEW; SCREENING TEST;

ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION TESTS; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 34548315929     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.089524     Document Type: Review

References (50)

1. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants [Review]. Thromb Haemost 2001;86:83-91.
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
3. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
4. Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem 2003;49:1608-14.
5. Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost 1997;77:934-7.
6. Brandt JT, Triplett DA, Rock WA, Bovill EG, Arkin CF. Effect of lupus anticoagulants on the activated partial thromboplastin time: results of the College of American Pathologists survey program. Arch Pathol Lab Med 1991;115:109-14.
7. Roussi J, Roisin JP, Goguel A. Lupus anticoagulants: first French interlaboratory Etalonorm survey. Am J Clin Pathol 1996;105:788-93.
8. Favaloro EJ, Bonar R, Sioufi J, Wheeler M, Low J, Aboud M, et al. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of the Australasia Quality Assurance Programs for Hematology. Sem Thromb Haemost 2005;31:49-58.
9. Favaloro EJ, Bonar R, Duncan E, Earl G, Low J, Aboud M, et al. (on behalf of the RCPAQAP in Haematology Haemostasis Committee). Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multicenter evaluation. Thromb Haemost 2006;96:73-8.
10. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost 1999;81:929-34.
11. Pengo V, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, et al. on behalf of participating centers of Italian Federation of Thrombosis Centers (FCSA). Survey on lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007;5:925-30.
12. Sletnes KE, Gravem K, Wisloff F. Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies. Thromb Res 1992;66:43-53.
13. Schjetlein R, Wisloff F. Detection of lupus anticoagulant: an evaluation of routines for preparation and storage of plasma. Thromb Res 1995;79:135-40.
14. Exner T. Conceptions and misconceptions in testing for lupus anticoagulants. J Autoimmun 2000;15:179-83.
15. Chantarangkul V, Tripodi A, Clerici M, Bressi C, Mannucci PM. Laboratory diagnosis of lupus anticoagulants; effect of residual platelets in plasma, assessed by Staclot LA and silica clotting time. Thromb Haemost 2002;87:854-8.
16. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-90.
17. Favaloro EJ. Preanalytical variables in coagulation testing. Blood Coagul Fibrinolysis 2007;18:86-9.
18. Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978;40:143-51.
19. Denis-Magdelaine A, Flahault A, Verdy E. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants. Haemostasis 1995;25:98-105.
20. Adcock DM, Marlar RA. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant. Arch Pathol Lab Med 1992;116:837-40.
21. Kelsey PR, Stevenson KJ, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time; the central role of phosphatidyl serine. Thromb Haemost 1984;52:172-5.
22. Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 1989;62:892-6.
23. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995;74:1597-603.
24. Tripodi A, Mancuso ME, Chantarangkul V, Clerici M, Bader R, Meroni PL, et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem 2005;51:1883-5.
25. Chantarangkul V, Tripodi A, Arbini A, Mannucci PM. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb Res 1992;67:355-65.
26. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986;68:869-74.
27. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein 1-dependent antiphospholipid antibodies. Blood 1995;86:617-23.
28. Pengo V, Biasiolo A, Rampazzo P, Brocco T. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 1999;81:256-8.
29. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. Beta2-glycoprotein l-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004;104:3598-602.
30. Moore GW, Savidge GF. Heterogeneity of Russell viper venom affects the sensitivity of the dilute Russell viper venom time to lupus anticoagulants. Blood Coagul Fibrinolysis 2004;15:279-82.
31. Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994;87:94-9.
32. Brancaccio V, Ames PR, Glynn J, lannaccone L, Mackie U. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency, and heparin is provided by comparing a sensitive and an insensitive APTT reagent. Blood Coagul Fibrinolysis 1997;8:155-60.
33. Gardiner C, MacKie IJ, Malia RG, Jones DW, Winter M, Leeming D, et al. The importance of locally derived reference ranges and standardized calculation of dilute Russell viper venom time results in screening for lupus anticoagulant. Br J Haematol 2000;111:1230-5.
34. Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 1987;57:144-7.
35. Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983;79:678-82.
36. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993;70:787-93.
37. Tripodi A, Chantarangkul V, Clerici M, Mannucci PM. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment: performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost 2002;88:583-6.
38. Feinstein DI. Acquired disorders of hemostasis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 3rd ed. Philadelphia: Lippincott, 1994:881-905.
39. Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisloff F. The Lupus Ratio test: an interlaboratory study on the detection of Lupus anticoagulants by an APTT-based, integrated, and semiquantitative test. Fifth International Survey of Lupus Anticoagulants ISLA 5. Thromb Haemost 2000;83:704-8.
40. Triplett DA, Stacker KF, Unger GA, Barna LK. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993;70:925-31.
41. Le Querrec A, Arnout J, Arnoux D, Borg JY, Caron C, Darnige L, et al. Quantification of lupus anticoagulants in clinical samples using anti-beta2GP1 and anti-prothrombin monoclonal antibodies. Thromb Haemost 2001;86:584-9.
42. Galli M, Comfurius P, Barbui T, Zwaal RF, Bevers EM. Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992;68:297-300.
43. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-32.
44. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome [Review]. Blood 2003;102:2717-23.
45. Simmelink MJ, Derksen RH, Arnout J, De Groot PG. A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003;1:740-7.
46. Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004;2:702-7.
47. Bowie EJ, Thompson JH Jr, Pascuzzi CA, Owen CA Jr. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963;62:416-30.
48. Esmon NL, Smirnov MD, Esmon CT. Thrombogenic mechanisms of antiphospholipid antibodies [Review]. Thromb Haemost 1997;78:79-82.
49. de Groot PG, Derksen RH. Pathophysiology of the antiphospholipid syndrome [Review]. J Thromb Haemost 2005;3:1854-60.
50. Galli M, Ruggeri L, Barbui T. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998;91:1999-2004.